Excessive bleeding as a result of trauma, surgery, bleeding disorders or other causes is the most common preventable cause of death in modern society. RxMP Therapeutics is developing novel systemically delivered hemostatic agents that are designed to arrest or prevent excessive bleeding, thereby improving health care outcomes and costs and reducing the need for transfused blood.